Artwork

āđ€āļ™āļ·āđ‰āļ­āļŦāļēāļˆāļąāļ”āļ—āļģāđ‚āļ”āļĒ Jon Chee āđ€āļ™āļ·āđ‰āļ­āļŦāļēāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāļ—āļąāđ‰āļ‡āļŦāļĄāļ” āļĢāļ§āļĄāļ–āļķāļ‡āļ•āļ­āļ™ āļāļĢāļēāļŸāļīāļ āđāļĨāļ°āļ„āļģāļ­āļ˜āļīāļšāļēāļĒāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļ­āļąāļ›āđ‚āļŦāļĨāļ”āđāļĨāļ°āļˆāļąāļ”āļŦāļēāđƒāļŦāđ‰āđ‚āļ”āļĒāļ•āļĢāļ‡āļˆāļēāļ Jon Chee āļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāđāļžāļĨāļ•āļŸāļ­āļĢāđŒāļĄāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāļ‚āļ­āļ‡āļžāļ§āļāđ€āļ‚āļē āļŦāļēāļāļ„āļļāļ“āđ€āļŠāļ·āđˆāļ­āļ§āđˆāļēāļĄāļĩāļšāļļāļ„āļ„āļĨāļ­āļ·āđˆāļ™āđƒāļŠāđ‰āļ‡āļēāļ™āļ—āļĩāđˆāļĄāļĩāļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ‚āļ­āļ‡āļ„āļļāļ“āđ‚āļ”āļĒāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļ­āļ™āļļāļāļēāļ• āļ„āļļāļ“āļŠāļēāļĄāļēāļĢāļ–āļ›āļāļīāļšāļąāļ•āļīāļ•āļēāļĄāļ‚āļąāđ‰āļ™āļ•āļ­āļ™āļ—āļĩāđˆāđāļŠāļ”āļ‡āđ„āļ§āđ‰āļ—āļĩāđˆāļ™āļĩāđˆ https://th.player.fm/legal
Player FM - āđāļ­āļ› Podcast
āļ­āļ­āļŸāđ„āļĨāļ™āđŒāļ”āđ‰āļ§āļĒāđāļ­āļ› Player FM !

🧎 Neela Patel - Bonum Therapeutics - Part 3 | Developing Pipeline Strategy at Poniard Pharmaceuticals | Business & Corporate Development in Oncology | Transitioning from Abbott to AbbVie to Seagen

40:06
 
āđāļšāđˆāļ‡āļ›āļąāļ™
 

Manage episode 447260785 series 3461709
āđ€āļ™āļ·āđ‰āļ­āļŦāļēāļˆāļąāļ”āļ—āļģāđ‚āļ”āļĒ Jon Chee āđ€āļ™āļ·āđ‰āļ­āļŦāļēāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāļ—āļąāđ‰āļ‡āļŦāļĄāļ” āļĢāļ§āļĄāļ–āļķāļ‡āļ•āļ­āļ™ āļāļĢāļēāļŸāļīāļ āđāļĨāļ°āļ„āļģāļ­āļ˜āļīāļšāļēāļĒāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļ­āļąāļ›āđ‚āļŦāļĨāļ”āđāļĨāļ°āļˆāļąāļ”āļŦāļēāđƒāļŦāđ‰āđ‚āļ”āļĒāļ•āļĢāļ‡āļˆāļēāļ Jon Chee āļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāđāļžāļĨāļ•āļŸāļ­āļĢāđŒāļĄāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāļ‚āļ­āļ‡āļžāļ§āļāđ€āļ‚āļē āļŦāļēāļāļ„āļļāļ“āđ€āļŠāļ·āđˆāļ­āļ§āđˆāļēāļĄāļĩāļšāļļāļ„āļ„āļĨāļ­āļ·āđˆāļ™āđƒāļŠāđ‰āļ‡āļēāļ™āļ—āļĩāđˆāļĄāļĩāļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ‚āļ­āļ‡āļ„āļļāļ“āđ‚āļ”āļĒāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļ­āļ™āļļāļāļēāļ• āļ„āļļāļ“āļŠāļēāļĄāļēāļĢāļ–āļ›āļāļīāļšāļąāļ•āļīāļ•āļēāļĄāļ‚āļąāđ‰āļ™āļ•āļ­āļ™āļ—āļĩāđˆāđāļŠāļ”āļ‡āđ„āļ§āđ‰āļ—āļĩāđˆāļ™āļĩāđˆ https://th.player.fm/legal
Part 3 of 4:

Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.

Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss.

Join us this week to hear about:

  • Neela’s transition from Genentech to Poniard Pharmaceuticals
  • Her collaboration with Greg Hageman on age-related macular degeneration
  • Raising $37 million in Series A financing
  • Neela’s role at Poniard developing pipeline strategy with the head of chemistry
  • Her experiences at Abbott and AbbVie as Director of Global External Research and Search & Evaluation, respectively.

Please enjoy Jon’s conversation with Neela Patel!


Find Our Guest, Neela Patel, at these links:

Find Our Host, Jon Chee, at these links:

Excedr Socials & Website

Enriched Notes:

Topics Mentioned:
Antibody Drug Conjugates (Prime Antibody): https://www.excedr.com/resources/primary-antibody

People Mentioned:

Timestamps:
00:28 Intro
01:50 Starting a company after Genentech experience
02:36 Greg Hageman’s key gene discovery and securing Series A funding
05:32 Developing pipeline strategy at Poniard
06:43 Transitioning to BD (Search and Evaluation) at Abbott
12:31 Spinning out AbbVie, Neela’s continued focus on Oncology
14:58 Fostering innovation and external ideas at AbbVie
16:51 Evaluating small companies & the biggest challenge of Search and Evaluation
20:13 Key factors for startups looking to partner with big pharma
26:32 Transitioning to Seattle Genetics (Seagen) and Corporate Development
29:28 Neela’s CorpDev experience, navigating unique challenges
34:03 Understanding how to diversify revenue streams and navigate cycles
39:01 Outro
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

101 āļ•āļ­āļ™

Artwork
iconāđāļšāđˆāļ‡āļ›āļąāļ™
 
Manage episode 447260785 series 3461709
āđ€āļ™āļ·āđ‰āļ­āļŦāļēāļˆāļąāļ”āļ—āļģāđ‚āļ”āļĒ Jon Chee āđ€āļ™āļ·āđ‰āļ­āļŦāļēāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāļ—āļąāđ‰āļ‡āļŦāļĄāļ” āļĢāļ§āļĄāļ–āļķāļ‡āļ•āļ­āļ™ āļāļĢāļēāļŸāļīāļ āđāļĨāļ°āļ„āļģāļ­āļ˜āļīāļšāļēāļĒāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļ­āļąāļ›āđ‚āļŦāļĨāļ”āđāļĨāļ°āļˆāļąāļ”āļŦāļēāđƒāļŦāđ‰āđ‚āļ”āļĒāļ•āļĢāļ‡āļˆāļēāļ Jon Chee āļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāđāļžāļĨāļ•āļŸāļ­āļĢāđŒāļĄāļžāļ­āļ”āđāļ„āļŠāļ•āđŒāļ‚āļ­āļ‡āļžāļ§āļāđ€āļ‚āļē āļŦāļēāļāļ„āļļāļ“āđ€āļŠāļ·āđˆāļ­āļ§āđˆāļēāļĄāļĩāļšāļļāļ„āļ„āļĨāļ­āļ·āđˆāļ™āđƒāļŠāđ‰āļ‡āļēāļ™āļ—āļĩāđˆāļĄāļĩāļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ‚āļ­āļ‡āļ„āļļāļ“āđ‚āļ”āļĒāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļ­āļ™āļļāļāļēāļ• āļ„āļļāļ“āļŠāļēāļĄāļēāļĢāļ–āļ›āļāļīāļšāļąāļ•āļīāļ•āļēāļĄāļ‚āļąāđ‰āļ™āļ•āļ­āļ™āļ—āļĩāđˆāđāļŠāļ”āļ‡āđ„āļ§āđ‰āļ—āļĩāđˆāļ™āļĩāđˆ https://th.player.fm/legal
Part 3 of 4:

Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.

Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss.

Join us this week to hear about:

  • Neela’s transition from Genentech to Poniard Pharmaceuticals
  • Her collaboration with Greg Hageman on age-related macular degeneration
  • Raising $37 million in Series A financing
  • Neela’s role at Poniard developing pipeline strategy with the head of chemistry
  • Her experiences at Abbott and AbbVie as Director of Global External Research and Search & Evaluation, respectively.

Please enjoy Jon’s conversation with Neela Patel!


Find Our Guest, Neela Patel, at these links:

Find Our Host, Jon Chee, at these links:

Excedr Socials & Website

Enriched Notes:

Topics Mentioned:
Antibody Drug Conjugates (Prime Antibody): https://www.excedr.com/resources/primary-antibody

People Mentioned:

Timestamps:
00:28 Intro
01:50 Starting a company after Genentech experience
02:36 Greg Hageman’s key gene discovery and securing Series A funding
05:32 Developing pipeline strategy at Poniard
06:43 Transitioning to BD (Search and Evaluation) at Abbott
12:31 Spinning out AbbVie, Neela’s continued focus on Oncology
14:58 Fostering innovation and external ideas at AbbVie
16:51 Evaluating small companies & the biggest challenge of Search and Evaluation
20:13 Key factors for startups looking to partner with big pharma
26:32 Transitioning to Seattle Genetics (Seagen) and Corporate Development
29:28 Neela’s CorpDev experience, navigating unique challenges
34:03 Understanding how to diversify revenue streams and navigate cycles
39:01 Outro
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

101 āļ•āļ­āļ™

āļ—āļļāļāļ•āļ­āļ™

×
 
Loading …

āļ‚āļ­āļ•āđ‰āļ­āļ™āļĢāļąāļšāļŠāļđāđˆ Player FM!

Player FM āļāļģāļĨāļąāļ‡āļŦāļēāđ€āļ§āđ‡āļš

 

āļ„āļđāđˆāļĄāļ·āļ­āļ­āđ‰āļēāļ‡āļ­āļīāļ‡āļ”āđˆāļ§āļ™